Board of Directors
Joe Bress is a principal at The Carlyle Group focused on private equity opportunities in the health care sector. He is based in New York.
Since joining Carlyle in 2007, Mr. Bress has been involved in investing and managing more than $4 billion of equity investments into health care companies globally.
He currently sits on the board of directors of PPD, WellDyneRx, Albany Molecular Research, Visionary RCM, Millicent Pharma and X-Co Holdings (the parent company of X-Chem and X-Rx). He is also involved in Carlyle’s investment in Rede D’Or Sao Luiz.
Prior to Carlyle, he worked in the mergers and acquisitions group at UBS.
Mr. Bress received an MBA from Stanford University’s Graduate School of Business and an AB from Harvard College, where he graduated magna cum laude.